LeConte Wealth Management
ALNY icon

LeConte Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

LeConte Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-759
Closed -$228K – 199
2026
Q2 		$228K Buy
759
+64
+9% +$19.3K 0.12% 140
2026
Q1 		$230K Buy
695
+91
+15% +$31K 0.15% 123
2025
Q4 		$240K Buy
604
+78
+15% +$34.5K 0.16% 106
2025
Q3 		$240K Buy
+526
New +$214K 0.16% 101

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

LeConte Wealth Management's ALNY Position: Q3 2026 in Review

LeConte Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 759 shares — an estimated $228K sold.

LeConte Wealth Management first reported a position in ALNY in Q3 2025 and held it in 4 quarters. The position peaked at $240K in Q4 2025. 403 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • LeConte Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • LeConte Wealth Management sold 759 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $228K.
  • LeConte Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 4 quarters.
  • LeConte Wealth Management's Alnylam Pharmaceuticals position peaked at $240K in Q4 2025.
  • 403 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on LeConte Wealth Management's 13F filing for Q3 2026, filed 20 Oct 2026.